Skip to main content
. 2014 Apr 10;28(1-2):53–69. doi: 10.3109/01677063.2014.882918

Table 1.

Subjects included in this study.

Group Sexa Ageb PMIc pH Smoker Cause of death Antipsychoticd
Control F 79 15.00 6.59 Yes Cardiac arrest N/A
Control M 22 21.47 6.75 Yes Myocardial infarction N/A
Control M 75 20.25 6.35 Yes Unknown N/A
Control M 80 15.50 6.26 Yes Myocardial infarction N/A
Control F 58 21.08 6.79 No Myocardial infarction N/A
Control M 61 17.00 6.64 Yes Unknown N/A
Control F 71 20.50 6.89 Unknown Unknown N/A
Control F 90 12.66 6.10 Unknown Lung cancer N/A
Control F 86 6.92 5.74 Unknown Myocardial infarction N/A
Mean ± SEM 4M/5F 69.11 ± 6.85 16.71 ± 1.60 6.46 ± 0.12
Schizophrenia F 93 6.92 6.13 Unknown Renal failure Perphenazine (50)
Schizophrenia M 55 21.40 6.51 Yes Myocardial infarction Perphenazine
Schizophrenia F 67 21.80 5.80 Unknown Pulmonary disease Thioridazine, prochlorperazine (200)
Schizophrenia F 55 22.00 5.90 Yes Cancer Clozapine, olanzapine
Schizophrenia M 36 17.97 6.45 Unknown Cardiac arrest Clozapine (350)
Schizophrenia M 62 10.75 6.50 Yes Chronic obstructive pulmonary disease, lung cancer Clozapine
Schizophrenia F 92 17.80 6.34 Unknown Cardiomyopathy Unknown
Schizophrenia M 56 21.83 6.75 No Car accident Olanzapine (150)
Schizophrenia F 88 13.33 6.65 No Unknown Thiothixene (50)
Mean ± SEM 4M/5F 68.11 ± 6.60 16.90 ± 1.85 6.34 ± 0.11
a

F = female; M = male.

b

Age is given in years.

c

PMI = postmortem interval in hours.

d

N/A = not applicable; numbers in parentheses indicate CED.